Clinical Trials in Meizhou, Guangdong
33 recruiting
Showing 1–20 of 32 trials
Recruiting
Phase 2
A ctDNA-guided Phase II Trial of Osimertinib in Combination With Sacituzumab Tirumotecan in EGFR-mutated Advanced NSCLC Patients With Positive ctDNA After lead-in Osimertinib Monotherapy
Non-small Cell Lung Cancer
Guangdong Association of Clinical Trials120 enrolled4 locationsNCT07375316
Recruiting
Phase 3
A Study of BGB-16673 Compared to Investigator's Choice in Participants With Relapsed/Refractory Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma Previously Exposed to Covalent Bruton Tyrosine Kinase (BTK) Inhibitors
Chronic Lymphocytic LeukemiaSmall Lymphocytic Lymphoma
BeOne Medicines150 enrolled64 locationsNCT06970743
Recruiting
Phase 3
BDB-001 Phase III Trial in ANCA-Associated Vasculitis
ANCA Associated Vasculitis (AAV)
Staidson (Beijing) Biopharmaceuticals Co., Ltd300 enrolled60 locationsNCT07168161
Recruiting
Phase 3
A Study of Zanubrutinib Plus Anti-CD20 Versus Lenalidomide Plus Rituximab in Participants With Relapsed/Refractory Follicular or Marginal Zone Lymphoma
Marginal Zone LymphomaRelapsed/Refractory Follicular Lymphoma
BeiGene780 enrolled277 locationsNCT05100862
Recruiting
Phase 2
Tislelizumab (Anti-Programmed Cell Death Protein-1 (PD-1) Antibody) in MSI-H or dMMR Solid Tumors
MSI-H/dMMR Solid Tumors
BeiGene200 enrolled29 locationsNCT03736889
Recruiting
Phase 3
A Study of HX008 Compared to Chemotherapy in the First-Line Treatment of Subjects With MSI-H/dMMR Metastatic Colorectal Cancer
Metastatic Colorectal Cancer
Taizhou Hanzhong biomedical co. LTD190 enrolled63 locationsNCT05652894
Recruiting
Phase 3
A Study of Tucatinib With Trastuzumab and mFOLFOX6 Versus Standard of Care Treatment in First-line HER2+ Metastatic Colorectal Cancer
Colorectal Neoplasms
Seagen, a wholly owned subsidiary of Pfizer400 enrolled382 locationsNCT05253651
Recruiting
Phase 3
A Clinical Study of Neoadjuvant Treatment With TQB2102 for Injection for Human Epidermal Growth Factor Receptor 2 (HER2) Positive Breast Cancer
HER2-positive Breast Cancer
Chia Tai Tianqing Pharmaceutical Group Nanjing Shunxin Pharmaceutical Co., Ltd.544 enrolled78 locationsNCT07043725
Recruiting
A Prospective Cohort Study of Zorifertinib as a First-line Treatment in Patients With Epidermal Growth Factor Receptor-mutant Advanced Non-small Cell Lung Cancer With Central Nervous System (CNS) Metastases
EGFR Mutant Advanced Non-small Cell Lung CancerCentral Nervous System (CNS) Metastases
Alpha Biopharma (Jiangsu) Co., Ltd.800 enrolled34 locationsNCT07143045
Recruiting
Phase 1
A Phase I Clinical Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Preliminary Efficacy of TQB3122 Capsules in Subjects With Advanced Malignant Tumors
Advanced Cancer
Chia Tai Tianqing Pharmaceutical Group Co., Ltd.86 enrolled5 locationsNCT07269145
Recruiting
Phase 3
JS107 vs Investigator's Choice as Second-line or Later Therapy for Advanced CLDN18.2-Positive Gastricor GEJ Adenocarcinoma.
Advanced Gastric or Gastroesophageal Junction Adenocarcinoma
Shanghai Junshi Bioscience Co., Ltd.560 enrolled68 locationsNCT07284134
Recruiting
A Real World, Multi-centric, Observational Registry Study of Chronic Kidney Diseases
Chronic Kidney Disease
Guangdong Provincial People's Hospital90,000 enrolled8 locationsNCT05188885
Recruiting
Not Applicable
A Study of Pegmolesatide of in Dialysis Chronic Kidney Disease (CKD) Patients With Anemia Treated With Hypoxia-inducible Factor Prolyl Hydroxylase Inhibitor (HIF-PHI)
Renal Anemia of Chronic Kidney Disease
Guangdong Provincial People's Hospital96 enrolled24 locationsNCT07136792
Recruiting
Phase 3
Efficacy and Safety of Vedolizumab IV in Chinese Participants With Ulcerative Colitis
Moderately to Severely Active Ulcerative Colitis
Takeda402 enrolled36 locationsNCT03221036
Recruiting
Phase 2
A Study of Rocbrutinib in Participants With Relapse or Refractory Non-GCB Diffuse Large B-Cell Lymphoma
Diffuse Large B-Cell Lymphoma (DLBCL)
Guangzhou Lupeng Pharmaceutical Company LTD.150 enrolled41 locationsNCT07189065
Recruiting
Phase 2
A Study of YL202 in Selected Patients With Advanced Solid Tumors
Breast CancerNSCLCHNSCC+1 more
MediLink Therapeutics (Suzhou) Co., Ltd.200 enrolled82 locationsNCT06107686
Recruiting
Phase 4
ASPIrin in Reducing Events in Dialysis ( ASPIRED )
CKD (Chronic Kidney Disease) Stage 5D
Guangdong Provincial People's Hospital9,000 enrolled139 locationsNCT04381143
Recruiting
Phase 1Phase 2
A Study of YL202 in Combination With Other Anti-tumor Therapies in Patients With Advanced Solid Tumors
Breast CancerNon-small Cell Lung CancerAdvanced Solid Tumors
MediLink Therapeutics (Suzhou) Co., Ltd.414 enrolled20 locationsNCT07169994
Recruiting
A Multi-center Study on Artificial Intelligence-Based Quantitative Evaluation of Echocardiography
Artificial Intelligence (AI)Cardiovascular Diseases (CVD)Echocardiography+1 more
First Hospital of China Medical University1,600 enrolled37 locationsNCT07133516
Recruiting
Phase 1Phase 2
TQB2922 and TAS-102 Tablets for Injection With or Without Bevacizumab in Chemotherapy-failed RAS/BRAF Wild-type Advanced Colorectal Cancer
RAS/BRAF Wild Type Colorectal Cancer
Chia Tai Tianqing Pharmaceutical Group Nanjing Shunxin Pharmaceutical Co., Ltd.72 enrolled27 locationsNCT07044908